Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
April 9, 2014
Verastem Presents Data on Cancer Stem Cell-Targeting Agents at the 2014 AACR Annual Meeting
March 25, 2014
Verastem to Present Data on Product Candidates Targeting Cancer Stem Cells at the American Association of Cancer Research Meeting
March 20, 2014
Verastem to Present at the Boston Business Development Conference
The majority of cancer drugs, while killing the bulk of tumor cells, ultimately fail to induce durable clinical responses. A reason for this failure may be the presence of a minority of cells in the tumor called cancer stem cells which are resistant to existing cancer therapies.
Using our proprietary technology we are identifying and developing drugs that target and kill cancer stem cells.